Metabolic Tumour Volume Is Prognostic in Patients with Non-Small-Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy | Zendy

Maryam Dosani | Zendy; Runlin Yang | Zendy; Mary McLay | Zendy; Don Wilson | Zendy; M. Liu | Zendy; Charlotte J. YongHing | Zendy; Jeremy Hamm | Zendy; C. Lund | Zendy; Robert Olson | Zendy; Devin Schellenberg | Zendy

Open Access

Metabolic Tumour Volume Is Prognostic in Patients with Non-Small-Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy

Author(s) -

Maryam Dosani,

Runlin Yang,

Mary McLay,

Don Wilson,

M. Liu,

Charlotte J. YongHing,

Jeremy Hamm,

C. Lund,

Robert Olson,

Devin Schellenberg

Publication year - 2019

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.26.4167

Subject(s) - sabr volatility model , medicine , lung cancer , standardized uptake value , positron emission tomography , stage (stratigraphy) , nuclear medicine , radiation therapy , univariate analysis , multivariate analysis , radiology , oncology , volatility (finance) , paleontology , stochastic volatility , biology , financial economics , economics

Stereotactic ablative radiotherapy (sabr) is a relatively new technique for the curative-intent treatment of patients with inoperable early-stage non-small-cell lung cancer (nsclc). Previous studies have demonstrated a prognostic value for positron emission tomography-computed tomography (pet/ct) parameters, including maximal standardized uptake value (suv max ), metabolic tumour volume (mtv), and total lesion glycolysis (tlg) in lung cancer patients. We aimed to determine which pet/ct parameter is most prognostic of local control (lc) and overall survival (os) in patients treated with sabr for nsclc.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research